Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Syntaxin binding protein 5 antisense RNA 1 (STXBP5-AS1)
- Target
- STXBP5-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Other (non-protein-coding transcript)
01
Overview
Syntaxin binding protein 5 antisense RNA 1 (STXBP5-AS1) is a long non-coding RNA gene implicated in tumor suppression, regulating cancer cell proliferation, apoptosis, DNA replication, cell cycle, and metastasis through multiple signaling pathways. Its expression is down-regulated in multiple cancers, including colon adenocarcinoma, where it serves as a prognostic biomarker. STXBP5-AS1 modulates gene networks associated with immune cell infiltration and can be a target for experimental therapy using small molecules identified via computational analysis, though no approved drugs act directly on it
- Other names
- STXBP5-AS1STXBP5 antisense RNA 1 (non-protein coding)HGNC:44183ENSG00000233452
02
Mechanism of action
Putative mechanisms include modulation of signaling pathways (e.g. PI3K/AKT, Wnt, mTORC1, TP53, NOTCH4) and epigenetic regulation; proposed drug actions include interacting with proteins or gene networks modulated by STXBP5-AS1, indirectly affecting cancer cell survival or proliferation
03
Biological functions
Tumor suppressionRegulation of cell proliferationRegulation of apoptosisModulation of cell cycleRegulation of DNA replicationInfluence on metastasisImmune cell gene expression modulationEpigenetic regulation
04
Disease associations
Cancer (colon adenocarcinoma, gastric cancer, cervical cancer, breast cancer, non-small cell lung carcinoma)Prognostic biomarkerCancer progression and metastasisRadiotherapy sensitivity
05
Safety considerations
Safety concerns not directly reported; as with other RNA-based targets, challenges may include off-target effects and delivery; further validation required for clinical application
06
Interacting drugs
Anisomycin
3 more in the full profile.
07
Biomarkers
STXBP5-AS1 RNA expression (prognostic marker in colon adenocarcinoma and other cancers; low expression predicts poor overall survival)
Beyond the preview
Go deeper on Syntaxin binding protein 5 antisense RNA 1 (STXBP5-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syntaxin binding protein 5 antisense RNA 1 (STXBP5-AS1).